AbbVie

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas –immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on X, Facebook, Instagram, YouTube, LinkedIn and Tik Tok.

1 North Waukegan Road
North Chicago, IL 60064

Visit website

Stock Symbol: ABBV
Stock Exchange: NYSE

Together, we break through.

Our principles are at the Heart of our Company. Operating as one AbbVie team, we care deeply for our patients, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. In everything we do, we invest and innovate relentlessly to tackle unmet needs, creating new medicines and healthcare approaches for a healthier world.

How we work with each other and achieve results matters. That’s why we’ve been honored to receive some of the most prestigious ratings and recognitions in the industry, including being named on more than 40 Great Place to Work and Top Employer lists and FORTUNE “100 Best Companies to Work For.”

Click here to learn more about our principles.

NEWS

Business

Spotlight on Biopharma Fellowships: AbbVie and Keck Graduate Institute Launch PharmD Fellowship Program

AbbVie and the Keck Graduate Institute (KGI) School of Pharmacy have partnered to form the first AbbVie-KGI Biopharmaceutical Industry Fellowship.

June 13, 2018

3 min read

Mark Terry

Policy

AbbVie Responds to FDA Criticism Over Manufacturing Complaints

The U.S. Food and Drug Administration (FDA) recently reprimanded AbbVie for its processes for investigating reports of deaths associated with three of its drugs.

June 12, 2018

2 min read

Mark Terry

FDA

AbbVie and Roche’s Venclexta and Rituxan Combo Gets FDA Approval

The U.S. Food and Drug Administration (FDA) approved AbbVie and Roche’s combination of Venclexta in combination with Rituxan (rituximab) to treat chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion in patients who have received at least one previous therapy.

June 11, 2018

2 min read

Mark Terry

Drug Development

AbbVie’s Upadacitinib Looks Good in Arthritis Trial; Rova-T Looks Worse in Lung Cancer

AbbVie announced positive topline results from its SELECT-EARLY Phase III clinical trial in rheumatoid arthritis, but disappointed with Rova-T small-cell lung cancer therapy.

June 5, 2018

2 min read

Mark Terry

Genetown

BIO 2018 is the International Convention’s 25th Year

The 2018 BIO International Convention will be officially running from June 4 through June 7 and is celebrating 25 years of innovation.

June 4, 2018

3 min read

Mark Terry

Gilead's $12B Bet Pays Off in Two Months After the

Drug Development

Primary Endpoint Hit: Gilead and Galapagos’ JAK1 Inhibitor for Arthritis Positive in Phase II

Gilead Sciences and its development partner Galapagos NV announced positive data from its Phase II EQUATOR trial of filgotinib in psoriatic arthritis.

May 31, 2018

3 min read

Mark Terry

BioMidwest

AbbVie Is a Great Short-Term Investment but Long-Term Is More Complicated

Over the last five years, AbbVie shares are up about 130 percent. It’s generally viewed as a volatile stock.

May 30, 2018

3 min read

Mark Terry

Ublituximab shows better results than Aubagio in p

BioMidwest

On World MS Day Companies Drive Toward a Cure as Patients, Advocates Join Together in Hope

Since 2009 May 30 has been set aside as a day to raise awareness and campaign for an end to multiple sclerosis. The theme this year is focused on the research being conducted to develop a cure for the neurological disease.

May 29, 2018

4 min read

Alex Keown

Drug Development

More Treatments for Multiple Myeloma Could Soon be Available for Patients

Within the next six years, the multiple myeloma market is projected to be $37.5 billion – an incredible growth of $30 billion since 2015, when the market was valued at about $7.5 billion.

May 29, 2018

4 min read

Alex Keown

JOBS